As of June 30, 2011, Biozone Pharmaceuticals, Inc. had cash and
cash equivalents of US$1,839,685 and negative working capital of
US$1,098,943. The Company had cash and cash equivalents of
US$251,475…
provides timely updates on public companies reporting a working capital deficit to the U.S. Securities and Exchange Commission. Companies with minimum total assets of USD $5 million are covered. Liquidity Alert highlights significant events affecting liquidity, cash flows, estimated capital expenditures, and capital raising efforts.